Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label randomized study of IZD174 in CAPS
2020-000489-40Phase 2Terminated
- Sponsor
- Inflazome
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inzomelid in cryopyrin-associated periodic syndrome (CAPS) (2 arms), sponsored by Inflazome. Primary endpoint: Safety and tolerability. Started Apr 2020; status: terminated.
02
Drugs
inzomelid
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2020-000489-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000489-40.